Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Mexico
12/12/2024 12:45
Dec 12 (Reuters) - Knight Therapeutics GUD.TO :
* KNIGHT THERAPEUTICS ANNOUNCES REGULATORY APPROVAL OF
TAVALISSE®
IN MEXICO
* KNIGHT THERAPEUTICS INC - TAVALISSE EXPECTED TO LAUNCH IN
MEXICO
IN FIRST HALF OF 2026
Source text: ID:nGNX2CVc1s
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil